Pfizer Inc. $PFE Shares Purchased by Goldstone Financial Group LLC

Goldstone Financial Group LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 53.8% in the second quarter, Holdings Channel reports. The firm owned 25,241 shares of the biopharmaceutical company’s stock after buying an additional 8,832 shares during the quarter. Goldstone Financial Group LLC’s holdings in Pfizer were worth $641,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Gould Capital LLC grew its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the 1st quarter valued at $27,000. North Capital Inc. acquired a new stake in Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Finally, Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.12.

Pfizer Stock Up 0.5%

Shares of NYSE:PFE opened at $23.98 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The stock has a market capitalization of $136.34 billion, a P/E ratio of 12.76, a PEG ratio of 0.85 and a beta of 0.55. The stock has a 50-day simple moving average of $24.76 and a 200-day simple moving average of $24.25.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer’s payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.